I agree that this site is using cookies. You can find further informations here.
X
Braeckman, Rene A.
45  results:
Search for persons X
?
1

0651 Pharmacokinetics of Morning and Nighttime Doses of KP1..:

Braeckman, Rene ; Smith, Adam ; Lubert, Adam.
SLEEP.  47 (2024)  Supplement_1 - p. A278-A279 , 2024
Link: https://doi.org/10.1093/..
 
?
2

Serdexmethylphenidate/dexmethylphenidate for children with ..:

Cutler, Andrew J. ; Kollins, Scott H. ; Brams, Matthew N....
Frontiers in Psychiatry.  15 (2024)  - p. , 2024
Link: https://doi.org/10.3389/..
 
?
3

Serdexmethylphenidate/dexmethylphenidate capsules for child..:

Kollins, Scott H. ; Marraffino, Andrea ; Cutler, Andrew J....
Future Neurology.  19 (2024)  1 - p. , 2024
Link: https://doi.org/10.2217/..
 
?
4

0650 Safety and Efficacy of KP1077 in a Phase 2, Double-Bli..:

Braeckman, Rene ; Drake, Christopher ; Gallo, Daniel..
SLEEP.  47 (2024)  Supplement_1 - p. A278-A278 , 2024
Link: https://doi.org/10.1093/..
 
?
5

A Study of Once-a-Week Donepezil Transdermal System's Bioeq..:

Braeckman, Rene ; Oh, Charles
Neurodegenerative Disease Management.  13 (2023)  6 - p. 303-313 , 2023
Link: https://doi.org/10.2217/..
 
?
6

Bioequivalence and safety comparison of once‐weekly donepez..:

Tariot, Pierre N. ; Braeckman, Rene ; Oh, Charles
Alzheimer's & Dementia.  18 (2022)  S10 - p. , 2022
Link: https://doi.org/10.1002/..
 
?
7

Comparison of Steady-State Pharmacokinetics of Donepezil Tr..:

Tariot, Pierre N. ; Braeckman, Rene ; Oh, Charles
Journal of Alzheimer's Disease.  90 (2022)  1 - p. 161-172 , 2022
Link: https://doi.org/10.3233/..
 
?
8

Oral, intranasal, and intravenous abuse potential of serdex..:

Shram, Megan J. ; Setnik, Beatrice ; Webster, Lynn...
Current Medical Research and Opinion.  38 (2022)  7 - p. 1237-1250 , 2022
Link: https://doi.org/10.1080/..
 
?
9

Pharmacokinetics and Abuse Potential of Asalhydromorphone, ..:

Vince, Bradley ; Kelsh, Debra ; Braeckman, Rene...
Pain Medicine.  21 (2019)  3 - p. 511-520 , 2019
Link: https://doi.org/10.1093/..
 
?
10

Rationale and design of REDUCE‐IT: Reduction of Cardiovascu..:

Bhatt, Deepak L. ; Steg, Ph. Gabriel ; Brinton, Eliot A....
Clinical Cardiology.  40 (2017)  3 - p. 138-148 , 2017
Link: https://doi.org/10.1002/..
 
?
11

Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effect..:

Ballantyne, Christie M. ; Bays, Harold E. ; Philip, Sephy...
Atherosclerosis.  253 (2016)  - p. 81-87 , 2016
Link: https://doi.org/10.1016/..
 
?
12

Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effect..:

Ballantyne, Christie M. ; Bays, Harold E. ; Braeckman, Rene A....
Journal of Clinical Lipidology.  10 (2016)  3 - p. 635-645.e1 , 2016
Link: https://doi.org/10.1016/..
 
?
13

Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effect..:

Ballantyne, Christie M. ; Bays, Harold E. ; Braeckman, Rene A....
Journal of Clinical Lipidology.  9 (2015)  3 - p. 463-464 , 2015
Link: https://doi.org/10.1016/..
 
?
14

Pharmacokinetic and Triglyceride-lowering Pharmacodynamic E..:

Stirtan, William G. ; Braeckman, Rene A. ; Bays, Harold E....
Journal of Clinical Lipidology.  9 (2015)  3 - p. 464 , 2015
Link: https://doi.org/10.1016/..
 
?
15

Effects of icosapent ethyl on lipoprotein particle concentr..:

Ballantyne, Christie M. ; Braeckman, Rene A. ; Bays, Harold E....
Journal of Clinical Lipidology.  9 (2015)  3 - p. 377-383 , 2015
Link: https://doi.org/10.1016/..
 
1-15